MCID: LMN006
MIFTS: 47

Luminal Breast Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma

MalaCards integrated aliases for Luminal Breast Carcinoma:

Name: Luminal Breast Carcinoma 12 15
Luminal Breast Cancer 12
Breast Tumor Luminal 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548

Summaries for Luminal Breast Carcinoma

MalaCards based summary : Luminal Breast Carcinoma, also known as luminal breast cancer, is related to in situ carcinoma and ductal carcinoma in situ. An important gene associated with Luminal Breast Carcinoma is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are Gene Expression and PI3K/AKT activation. Affiliated tissues include breast, lung and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Luminal Breast Carcinoma

Diseases related to Luminal Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 in situ carcinoma 29.9 EGFR ERBB2 ESR1 PGR
2 ductal carcinoma in situ 29.7 AKT1 EGFR ERBB2 ESR1 PGR
3 breast cancer 29.7 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1
4 scirrhous adenocarcinoma 10.3 ERBB2 PGR
5 breast apocrine carcinoma 10.3 ERBB2 PGR
6 vestibular gland benign neoplasm 10.3 ESR1 PGR
7 bartholin's gland adenoma 10.3 ESR1 PGR
8 comedo carcinoma 10.2 ERBB2 ESR1
9 breast intraductal proliferative lesion 10.2 EGFR ERBB2
10 vulvar syringoma 10.2 ESR1 PGR
11 lung leiomyoma 10.2 ESR1 PGR
12 intracystic papillary adenoma 10.2 ERBB2 PGR
13 breast metaplastic carcinoma 10.2 ERBB2 PGR
14 vulvar benign neoplasm 10.2 ESR1 PGR
15 trigonitis 10.2 ESR1 PGR
16 vulvar leiomyoma 10.2 ESR1 PGR
17 predominantly cortical thymoma 10.2 ESR1 PGR
18 paronychia 10.2 EGFR MTOR
19 progesterone resistance 10.2 ESR1 PGR
20 endometrial squamous cell carcinoma 10.2 ESR1 PGR
21 endometrial mucinous adenocarcinoma 10.2 ESR1 PGR
22 adenoid basal cell carcinoma 10.2 ESR1 PGR
23 peritoneal benign neoplasm 10.2 ESR1 PGR
24 gender identity disorder 10.2 ESR1 PGR
25 deep angioma 10.2 ESR1 PGR
26 diffuse peritoneal leiomyomatosis 10.2 ESR1 PGR
27 breast squamous cell carcinoma 10.2 EGFR ERBB2
28 synchronous bilateral breast carcinoma 10.2 ESR1 PGR
29 uterine body mixed cancer 10.2 ERBB2 PGR
30 female reproductive endometrioid cancer 10.2 ESR1 PGR
31 glassy cell carcinoma of the cervix 10.2 ERBB2 ESR1 PGR
32 cervical carcinosarcoma 10.2 ESR1 PGR
33 breast medullary carcinoma 10.2 ERBB2 ESR1 PGR
34 progesterone-receptor positive breast cancer 10.2 ERBB2 ESR1 PGR
35 breast adenoid cystic carcinoma 10.2 ERBB2 ESR1 PGR
36 apocrine adenocarcinoma 10.2 ERBB2 ESR1 PGR
37 breast benign neoplasm 10.2 ERBB2 ESR1 PGR
38 thoracic benign neoplasm 10.2 ERBB2 ESR1 PGR
39 angiomyolipoma 10.2 ESR1 MTOR PGR
40 uterine corpus cancer 10.2 ERBB2 ESR1 PGR
41 tubular adenocarcinoma 10.2 ERBB2 ESR1 PGR
42 fallopian tube carcinoma 10.2 ERBB2 ESR1 PGR
43 exanthem 10.2 EGFR ERBB2 MTOR
44 breast fibroadenoma 10.2 ERBB2 ESR1 PGR
45 female breast cancer 10.2 ERBB2 ESR1 PGR
46 hidradenocarcinoma 10.2 EGFR ERBB2 ESR1
47 cervical adenocarcinoma 10.2 ERBB2 ESR1 PGR
48 lymphangioleiomyomatosis 10.1 ESR1 MTOR PGR
49 sporadic breast cancer 10.1 ERBB2 ESR1 PGR
50 estrogen excess 10.1 ESR1 PGR

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma:



Diseases related to Luminal Breast Carcinoma

Symptoms & Phenotypes for Luminal Breast Carcinoma

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 66)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.53 FOXA1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 10.53 TFAP2C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.53 ERBB3 FOXA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.53 TFAP2C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.53 ERBB2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.53 MTOR
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.53 TFAP2C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.53 AKT1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.53 ERBB3 FOXA1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.53 FOXA1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.53 ERBB3 FOXA1 MTOR TFAP2C
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.53 ERBB3 MTOR AKT1 ERBB2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.53 ERBB2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.53 TFAP2C
15 Decreased viability GR00055-A-2 10.42 EGFR MTOR
16 Decreased viability GR00106-A-0 10.42 ERBB3
17 Decreased viability GR00221-A-1 10.42 AKT1 EGFR ESR1 MTOR
18 Decreased viability GR00221-A-2 10.42 AKT1 ERBB3 ESR1
19 Decreased viability GR00221-A-3 10.42 AKT1 ERBB2
20 Decreased viability GR00221-A-4 10.42 AKT1 EGFR ERBB2 ERBB3 ESR1 MTOR
21 Decreased viability GR00301-A 10.42 ERBB3
22 Decreased viability GR00342-S-1 10.42 MTOR
23 Decreased viability GR00342-S-2 10.42 ERBB3 MTOR
24 Decreased viability GR00342-S-3 10.42 ERBB3
25 Decreased viability GR00402-S-2 10.42 AKT1 EGFR ERBB2 ERBB3 ESR1 MTOR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.24 MTOR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.24 MTOR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.24 TFAP2C FOXA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.24 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.24 ERBB3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.24 EGFR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.24 TFAP2C FOXA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.24 TFAP2C
34 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.24 FOXA1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.24 TFAP2C
36 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.24 AKT1 ERBB3 MTOR TFAP2C FOXA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.24 ERBB2 TFAP2C
38 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.24 ERBB2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.24 ERBB2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.24 AKT1 FOXA1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.24 FOXA1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.24 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.24 ERBB3
44 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.24 FOXA1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.24 ERBB2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.24 EGFR
47 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.24 EGFR TFAP2C FOXA1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.24 ERBB2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.24 AKT1 MTOR FOXA1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.24 EGFR

MGI Mouse Phenotypes related to Luminal Breast Carcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.19 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
2 growth/size/body region MP:0005378 10.18 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1
3 embryo MP:0005380 10.16 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
4 cardiovascular system MP:0005385 10.15 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
5 endocrine/exocrine gland MP:0005379 10.15 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1
6 immune system MP:0005387 10.11 AKT1 EGFR ERBB3 ESR1 FOXA1 GATA3
7 mortality/aging MP:0010768 10.1 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1
8 integument MP:0010771 10.03 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1
9 digestive/alimentary MP:0005381 10 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
10 muscle MP:0005369 9.97 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
11 nervous system MP:0003631 9.91 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
12 neoplasm MP:0002006 9.87 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1
13 normal MP:0002873 9.81 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
14 respiratory system MP:0005388 9.43 AKT1 EGFR ERBB2 ERBB3 ESR1 MTOR
15 skeleton MP:0005390 9.17 AKT1 EGFR ERBB2 ESR1 GATA3 MTOR

Drugs & Therapeutics for Luminal Breast Carcinoma

Search Clinical Trials , NIH Clinical Center for Luminal Breast Carcinoma

Genetic Tests for Luminal Breast Carcinoma

Anatomical Context for Luminal Breast Carcinoma

MalaCards organs/tissues related to Luminal Breast Carcinoma:

41
Breast, Lung, Bone, Ovary, Prostate, Smooth Muscle, Thymus

Publications for Luminal Breast Carcinoma

Articles related to Luminal Breast Carcinoma:

(show top 50) (show all 98)
# Title Authors Year
1
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα. ( 30315845 )
2019
2
First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. ( 29715116 )
2018
3
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. ( 30518851 )
2018
4
Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. ( 30497520 )
2018
5
Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. ( 30442981 )
2018
6
DSCAM-AS1 regulates the G1 /S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy. ( 30430768 )
2018
7
Luminal breast cancer-specific circular RNAs uncovered by a novel tool for data analysis. ( 29581865 )
2018
8
The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. ( 29587760 )
2018
9
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. ( 29618617 )
2018
10
Identification of methylation sites and signature genes with prognostic value for luminal breast cancer. ( 29642861 )
2018
11
Collagen analysis by second-harmonic generation microscopy predicts outcome of luminal breast cancer. ( 29663855 )
2018
12
Combination of SIRT1 and Src overexpression suggests poor prognosis in luminal breast cancer. ( 29695913 )
2018
13
Somatic mutations in early onset luminal breast cancer. ( 29854292 )
2018
14
ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. ( 29854295 )
2018
15
Apparent diffusion coefficient measurement in luminal breast cancer: will tumour shrinkage patterns affect its efficacy of evaluating the pathological response? ( 29970246 )
2018
16
Optimal management of luminal breast cancer: how much endocrine therapy is long enough? ( 29977350 )
2018
17
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. ( 30038216 )
2018
18
Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors. ( 30065701 )
2018
19
Increased epigenetic age in normal breast tissue from luminal breast cancer patients. ( 30157950 )
2018
20
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. ( 30307466 )
2018
21
Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. ( 28865009 )
2018
22
Questions about Ki67 staining in luminal breast cancer. ( 28956199 )
2018
23
Response letter to: Questions about Ki67 staining in luminal breast cancer. ( 28956205 )
2018
24
BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes. ( 29138235 )
2018
25
Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. ( 29162724 )
2018
26
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. ( 29207087 )
2018
27
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer. ( 29353882 )
2018
28
Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes? ( 29373911 )
2018
29
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference? ( 29527939 )
2018
30
Immediate breast reconstruction with omental flap for luminal breast cancer patients: Ten clinical case reports. ( 28816969 )
2017
31
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. ( 27770345 )
2017
32
Reply: 18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer. ( 27932559 )
2017
33
A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method. ( 28187177 )
2017
34
Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells. ( 28242709 )
2017
35
Basal markers and prognosis in luminal breast cancer. ( 28258354 )
2017
36
18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer. ( 28373394 )
2017
37
Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. ( 28377607 )
2017
38
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. ( 28539475 )
2017
39
The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. ( 28625568 )
2017
40
De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. ( 28676389 )
2017
41
Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. ( 28739755 )
2017
42
Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. ( 28775276 )
2017
43
Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. ( 28881673 )
2017
44
Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis. ( 28886403 )
2017
45
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. ( 28933369 )
2017
46
MiR-23a modulates X-linked inhibitor of apoptosis-mediated autophagy in human luminal breast cancer cell lines. ( 29113338 )
2017
47
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? ( 29234247 )
2017
48
Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. ( 29234248 )
2017
49
Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis. ( 29250484 )
2017
50
GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers. ( 29262572 )
2017

Variations for Luminal Breast Carcinoma

Expression for Luminal Breast Carcinoma

Search GEO for disease gene expression data for Luminal Breast Carcinoma.

Pathways for Luminal Breast Carcinoma

Pathways related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 AKT1 EGFR ERBB2 ESR1 MTOR PGR
2
Show member pathways
13.03 AKT1 EGFR ERBB2 ERBB3 MTOR
3
Show member pathways
12.91 AKT1 EGFR ERBB2 ERBB3 MTOR
4
Show member pathways
12.83 AKT1 EGFR ERBB2 ERBB3 MTOR
5
Show member pathways
12.79 AKT1 EGFR ERBB2 ERBB3 MTOR
6 12.77 AKT1 EGFR ERBB2 ESR1 MTOR
7
Show member pathways
12.67 AKT1 EGFR ERBB2 ERBB3 MTOR
8
Show member pathways
12.66 AKT1 ERBB2 ERBB3 ESR1 MTOR
9
Show member pathways
12.63 AKT1 EGFR ERBB2 ERBB3 ESR1 MTOR
10
Show member pathways
12.6 AKT1 EGFR ERBB2 ESR1 MTOR PGR
11
Show member pathways
12.48 AKT1 EGFR ERBB2 ERBB3 MTOR
12 12.44 EGFR ERBB2 ERBB3 MTOR
13
Show member pathways
12.44 AKT1 EGFR ERBB2 ERBB3 MTOR
14
Show member pathways
12.42 AKT1 ELF5 ERBB2 ESR1 MTOR
15
Show member pathways
12.4 AKT1 EGFR ERBB2 ERBB3 MTOR
16
Show member pathways
12.33 AKT1 EGFR ERBB2 ERBB3 MTOR
17
Show member pathways
12.26 AKT1 EGFR ERBB2 ERBB3
18
Show member pathways
12.16 AKT1 EGFR ERBB2 ERBB3 ESR1
19 12.13 AKT1 EGFR ERBB2 MTOR
20
Show member pathways
12.11 AKT1 EGFR ERBB2 ERBB3 MTOR
21 12.1 AKT1 EGFR ESR1 MTOR
22
Show member pathways
12.07 AKT1 EGFR ERBB2 MTOR
23
Show member pathways
12.06 AKT1 EGFR ERBB2
24 12.05 EGFR ERBB2 ERBB3
25
Show member pathways
12.01 AKT1 EGFR ERBB2 ERBB3
26
Show member pathways
11.98 AKT1 EGFR ERBB2 ERBB3
27
Show member pathways
11.97 AKT1 EGFR MTOR
28 11.93 AKT1 ESR1 MTOR
29 11.9 AKT1 EGFR MTOR
30 11.87 AKT1 EGFR ERBB2 ERBB3 MTOR
31 11.86 AKT1 EGFR MTOR
32 11.85 AKT1 EGFR ERBB2 MTOR
33 11.83 AKT1 ESR1 MTOR
34 11.81 AKT1 EGFR MTOR
35
Show member pathways
11.76 EGFR ERBB2 ESR1 TFAP2C
36 11.72 AKT1 ESR1 GATA3
37
Show member pathways
11.69 EGFR ERBB2 ERBB3 ESR1 PGR
38 11.66 AKT1 EGFR ERBB2
39 11.57 EGFR ERBB2 ERBB3
40
Show member pathways
11.55 AKT1 EGFR ERBB2
41 11.52 AKT1 EGFR ESR1 MTOR
42 11.48 AKT1 EGFR ERBB2 MTOR
43 11.45 EGFR ERBB2 ERBB3
44 11.4 AKT1 EGFR ERBB2 ERBB3 ESR1 MTOR
45 11.31 AKT1 EGFR ERBB2 ERBB3 MTOR
46 11.07 AKT1 ESR1
47 10.97 AKT1 EGFR
48 10.95 AKT1 MTOR
49 10.95 AKT1 EGFR ERBB2 ERBB3
50 10.73 AKT1 EGFR ERBB2 MTOR

GO Terms for Luminal Breast Carcinoma

Cellular components related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 AKT1 EGFR ELF5 ERBB2 ESR1 FOXA1
2 basal plasma membrane GO:0009925 9.13 EGFR ERBB2 ERBB3
3 protein-containing complex GO:0032991 9.1 AKT1 EGFR ESR1 MTOR WWC1 ZNF703
4 cytoplasm GO:0005737 10 AKT1 EGFR ELF5 ERBB2 ERBB3 ESR1

Biological processes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 AKT1 EGFR ELF5 ERBB2
2 positive regulation of gene expression GO:0010628 9.96 AKT1 ERBB2 ERBB3 GATA3 MTOR
3 negative regulation of gene expression GO:0010629 9.92 AKT1 ESR1 GATA3 PGR
4 positive regulation of protein phosphorylation GO:0001934 9.87 AKT1 EGFR ERBB2 MTOR
5 negative regulation of signal transduction GO:0009968 9.86 EGFR ERBB2 ERBB3
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 AKT1 ESR1 FOXA1
7 response to estradiol GO:0032355 9.85 EGFR ESR1 FOXA1
8 male gonad development GO:0008584 9.85 ESR1 GATA3 TFAP2C
9 protein autophosphorylation GO:0046777 9.84 AKT1 EGFR ERBB2 MTOR
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 EGFR ERBB2 ERBB3
11 chromatin remodeling GO:0006338 9.82 ESR1 FOXA1 GATA3
12 positive regulation of cell growth GO:0030307 9.8 AKT1 EGFR ERBB2
13 positive regulation of MAPK cascade GO:0043410 9.78 EGFR ERBB2 ERBB3 WWC1
14 cellular response to growth factor stimulus GO:0071363 9.76 AKT1 EGFR ERBB2
15 positive regulation of transcription by RNA polymerase II GO:0045944 9.76 AKT1 EGFR ELF5 ESR1 FOXA1 GATA3
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 AKT1 EGFR MTOR
17 cellular response to epidermal growth factor stimulus GO:0071364 9.72 AKT1 EGFR ERBB2
18 phosphatidylinositol phosphorylation GO:0046854 9.71 EGFR ERBB2 ERBB3 ESR1
19 anatomical structure formation involved in morphogenesis GO:0048646 9.7 FOXA1 GATA3
20 regulation of nitric-oxide synthase activity GO:0050999 9.7 AKT1 EGFR
21 uterus development GO:0060065 9.69 ESR1 GATA3
22 positive regulation of lipid biosynthetic process GO:0046889 9.69 AKT1 MTOR
23 regulation of myelination GO:0031641 9.68 AKT1 MTOR
24 negative regulation of macroautophagy GO:0016242 9.68 AKT1 MTOR
25 cellular response to estradiol stimulus GO:0071392 9.67 EGFR ESR1 ZNF703
26 wound healing GO:0042060 9.67 EGFR ERBB2 ERBB3 MTOR
27 anoikis GO:0043276 9.65 AKT1 MTOR
28 positive regulation of transcription by RNA polymerase III GO:0045945 9.65 ERBB2 MTOR
29 negative regulation of cell size GO:0045792 9.63 AKT1 MTOR
30 ERBB2 signaling pathway GO:0038128 9.63 EGFR ERBB2 ERBB3
31 obsolete positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.61 AKT1 EGFR
32 regulation of glycogen biosynthetic process GO:0005979 9.61 AKT1 MTOR
33 regulation of cell motility GO:2000145 9.61 EGFR ERBB2 ERBB3
34 negative regulation of ERBB signaling pathway GO:1901185 9.59 EGFR ERBB2
35 response to UV-A GO:0070141 9.51 AKT1 EGFR
36 TOR signaling GO:0031929 9.5 AKT1 GATA3 MTOR
37 mammary gland epithelial cell differentiation GO:0060644 9.43 AKT1 ELF5 ZNF703
38 phosphatidylinositol 3-kinase signaling GO:0014065 9.26 AKT1 ERBB2 ERBB3 GATA3
39 positive regulation of protein kinase B signaling GO:0051897 9.1 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR
40 signal transduction GO:0007165 10.21 AKT1 EGFR ERBB2 ERBB3 ESR1 GATA3
41 regulation of transcription, DNA-templated GO:0006355 10.16 ELF5 ESR1 FOXA1 GATA3 PGR TFAP2C
42 negative regulation of transcription by RNA polymerase II GO:0000122 10.09 ESR1 FOXA1 GATA3 TFAP2C WWC1
43 cell differentiation GO:0030154 10.08 AKT1 EGFR ELF5 ERBB2 ERBB3 FOXA1
44 regulation of transcription by RNA polymerase II GO:0006357 10.07 EGFR ELF5 ERBB2 ESR1 FOXA1 GATA3
45 phosphorylation GO:0016310 10.06 AKT1 EGFR ERBB2 ERBB3 MTOR
46 protein phosphorylation GO:0006468 10.05 AKT1 EGFR ERBB2 ERBB3 MTOR
47 transcription by RNA polymerase II GO:0006366 10.04 ELF5 ESR1 FOXA1 GATA3 TFAP2C

Molecular functions related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.91 ELF5 ESR1 FOXA1 GATA3 PGR TFAP2C
2 kinase activity GO:0016301 9.89 AKT1 EGFR ERBB2 ERBB3 MTOR
3 sequence-specific DNA binding GO:0043565 9.88 ELF5 ESR1 FOXA1 GATA3 PGR
4 protein kinase activity GO:0004672 9.85 AKT1 EGFR ERBB2 ERBB3 MTOR
5 identical protein binding GO:0042802 9.8 AKT1 EGFR ERBB2 ERBB3 ESR1 MTOR
6 nucleotide binding GO:0000166 9.77 AKT1 EGFR ERBB2 ERBB3 MTOR
7 enzyme binding GO:0019899 9.72 AKT1 EGFR ESR1 PGR PREX1
8 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.7 EGFR ERBB2 ERBB3
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR ERBB2 ERBB3
10 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.55 ESR1 FOXA1 GATA3 PGR TFAP2C
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR ERBB2 ERBB3 ESR1
12 nitric-oxide synthase regulator activity GO:0030235 8.8 AKT1 EGFR ESR1
13 protein binding GO:0005515 10.32 AKT1 EGFR ERBB2 ERBB3 ESR1 FOXA1

Sources for Luminal Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....